Mesohaline Submerged Aquatic Vegetation Survey Along the U.S. Gulf of Mexico Coast, 2001 and 2002: A Salinity Gradient Approach

Distribution of marine submerged aquatic vegetation (SAV; i.e., seagrass) in the northern Gulf of Mexico coast has been documented, but there are nonmarine submersed or SAV species occurring in estuarine salinities that have not been extensively reported. We sampled 276 SAV beds along the gulf coast in Florida, Alabama, Mississippi, Louisiana, and Texas in 2001 and 2002 in oligohaline to polyhaline (0 to 36 parts per thousand) waters to determine estuarine SAV species distribution and identify mesohaline SAV communities. A total of 20 SAV and algal species was identified and habitat characteristics such as salinity, water depth, pH, conductivity, turbidity, dissolved oxygen, and sediment composition were collected. Fourteen SAV species occurred two or more times in our samples. The most frequently occurring species was Ruppia maritima L. (n = 148), occurring in over half of SAV beds sampled. Eleocharis sp. (n = 47), characterized with an emergent rather than submerged growth form, was a common genus in the SAV beds sampled. A common marine species was Halodule wrightii Asch. (n = 36). Nonindigenous species Myriophyllum spicatum L. (n = 31) and Hydrilla verticillata (L. f.) Royle (n = 6) were present only in oligohaline water. Analyzing species occurrence and environmental characteristics using canonical correspondence and two-way indicator species analysis, we identify five species assemblages distinguished primarily by salinity and depth. Our survey increases awareness of nonmarine SAV as a natural resource in the gulf, and provides baseline data for future research

Mesohaline Submerged Aquatic Vegetation Survey Along the U.S. Gulf of Mexico Coast, 2000: A Stratified Random Approach

Estimates of submerged aquatic vegetative (SAV) along the U.S. Gulf of Mexico (Gulf) generally focus on seagrasses. In 2000, we attempted a synoptic survey of SAV in the mesohaline (5–20 ppt) zone of estuarine and nearshore areas of the northeastern Gulf. Areas with SAV were identified from existing aerial 1992 photography, and a literature review was used to select those areas that were likely to experience mesohaline conditions during the growing season. In 2000, a drought year, we visited 217 randomly selected SAV beds and collected data on species composition and environmental conditions. In general, sites were either clearly polyhaline (≥ 20 ppt) or oligohaline (≤ 5 ppt), with only five sites measuring between 5 and 20 ppt. Ruppia maritima L. (13–35 ppt, n = 28) was the only species that occurred in mesohaline salinities. Halodule wrightii Asch. occurred in 73% of the beds. The nonindigenous Myriophyllum spicatum L. was present in four locations with salinities below 3 ppt. No nonindigenous macroalgae were identified, and no nonindigenous angiosperms occurred in salinities above 3 ppt. Selecting sample locations based on historical salinity data was not a successful strategy for surveying SAV in mesohaline systems, particularly during a drought year. Our ability to locate SAV beds within 50 m of their aerially located position 8 yr later demonstrates some SAV stability in the highly variable conditions of the study area

Arbuscular Mycorrhizae Occur in Common Spartina Species

We report the presence of arbuscular mycorrhizae (AM) in Spartina alterniflora Loisel roots. Roots were sampled for AM in field-collected and greenhouse-maintained Spartina patens (Aiton) Muhl. and S. alterniflora, the dominant species of Louisiana’s brackish and saline marshes, respectively. Previous reports of AM association in these Spartina sp. are limited and conflicting. Field-collected S. alterniflora had minimal AM (2.4%), whereas 39.5% of the S. patens roots examined were AM colonized. Greenhouse conditions of reduced salinity [3 parts per thousand (ppt)] appeared to increase AM association for S. patens compared with field samples. AM occurrence varied significantly among the three sample sites. Our results of low AM association in S. alterniflora differ from previous studies and confirm one previous report of AM in S. patens. Confirming AM association previously thought to be nonexistent in S. alterniflora marshes is a necessary first step in determining if AM influence zonation and competition

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

Background: The phase III CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) trial established the combination of pertuzumab, trastuzumab and docetaxel as standard first-line therapy for human epidermal growth factor receptor 2 (HER2)-positive locally recurrent/metastatic breast cancer (LR/mBC). The multicentre single-arm PERtUzumab global SafEty (PERUSE) study assessed the safety and efficacy of pertuzumab and trastuzumab combined with investigator-selected taxane in this setting. Patients and methods: Eligible patients with inoperable HER2-positive LR/mBC and no prior systemic therapy for LR/mBC (except endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab and pertuzumab until disease progression or unacceptable toxicity. The primary endpoint was safety. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). Prespecified subgroup analyses included subgroups according to taxane, hormone receptor (HR) status and prior trastuzumab. Exploratory univariable analyses identified potential prognostic factors; those that remained significant in multivariable analysis were used to analyse PFS and OS in subgroups with all, some or none of these factors. Results: Of 1436 treated patients, 588 (41%) initially received paclitaxel and 918 (64%) had HR-positive disease. The most common grade 653 adverse events were neutropenia (10%, mainly with docetaxel) and diarrhoea (8%). At the final analysis (median follow-up: 5.7 years), median PFS was 20.7 [95% confidence interval (CI) 18.9-23.1] months overall and was similar irrespective of HR status or taxane. Median OS was 65.3 (95% CI 60.9-70.9) months overall. OS was similar regardless of taxane backbone but was more favourable in patients with HR-positive than HR-negative LR/mBC. In exploratory analyses, trastuzumab-pretreated patients with visceral disease had the shortest median PFS (13.1 months) and OS (46.3 months). Conclusions: Mature results from PERUSE show a safety and efficacy profile consistent with results from CLEOPATRA and median OS exceeding 5 years. Results suggest that paclitaxel is a valid alternative to docetaxel as backbone chemotherapy. Exploratory analyses suggest risk factors that could guide future trial design

Comparative genomics of the neglected human malaria parasite Plasmodium vivax

The human malaria parasite Plasmodium vivax is responsible for 25-40% of the ∼515 million annual cases of malaria worldwide. Although seldom fatal, the parasite elicits severe and incapacitating clinical symptoms and often causes relapses months after a primary infection has cleared. Despite its importance as a major human pathogen, P. vivax is little studied because it cannot be propagated continuously in the laboratory except in non-human primates. We sequenced the genome of P. vivax to shed light on its distinctive biological features, and as a means to drive development of new drugs and vaccines. Here we describe the synteny and isochore structure of P. vivax chromosomes, and show that the parasite resembles other malaria parasites in gene content and metabolic potential, but possesses novel gene families and potential alternative invasion pathways not recognized previously. Completion of the P. vivax genome provides the scientific community with a valuable resource that can be used to advance investigation into this neglected species

Onto better TRAILs for cancer treatment

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also known as Apo-2 ligand (Apo2L), is a member of the TNF cytokine superfamily. By cross-linking TRAIL-Receptor (TRAIL-R) 1 or TRAIL-R2, also known as death receptors 4 and 5 (DR4 and DR5), TRAIL has the capability to induce apoptosis in a wide variety of tumor cells while sparing vital normal cells. The discovery of this unique property among TNF superfamily members laid the foundation for testing the clinical potential of TRAIL-R-targeting therapies in the cancer clinic. To date, two of these therapeutic strategies have been tested clinically: (i) recombinant human TRAIL and (ii) antibodies directed against TRAIL-R1 or TRAIL-R2. Unfortunately, however, these TRAIL-R agonists have basically failed as most human tumors are resistant to apoptosis induction by them. It recently emerged that this is largely due to the poor agonistic activity of these agents. Consequently, novel TRAIL-R-targeting agents with increased bioactivity are currently being developed with the aim of rendering TRAIL-based therapies more active. This review summarizes these second-generation novel formulations of TRAIL and other TRAIL-R agonists, which exhibit enhanced cytotoxic capacity toward cancer cells, thereby providing the potential of being more effective when applied clinically than first-generation TRAIL-R agonists